Drug Trial Radar · NCT01359592
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
159
Actual
Start
Sep 2011
Primary completion
Jun 3, 2020
Study completion Dec 2023
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Comparing results of diagnostic procedures, such as PET scan and CT scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial studies how well PET-directed chemotherapy works in treating patients with limited-stage diffuse large B-cell lymphoma.
Conditions
- Lymphoma
Interventions
rituximabBiological
cyclophosphamideDrug
doxorubicin hydrochlorideDrug
prednisoneDrug
vincristine sulfateDrug
R-CHOP regimenOther
laboratory biomarker analysisOther
fludeoxyglucose F 18Radiation
selective external radiation therapyRadiation
yttrium Y 90 ibritumomab tiuxetanRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)Time frame: up to 5 years
Locations
240 sites in 1 country. Site status is shown where the registry gives one.
Providence Cancer Center
Anchorage, Alaska
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona
Aurora Presbyterian Hospital
Aurora, Colorado
Boulder Community Hospital
Boulder, Colorado
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado
St. Anthony Central Hospital
Denver, Colorado
Kaiser Permanente - Denver
Denver, Colorado
Porter Adventist Hospital
Denver, Colorado
Presbyterian - St. Luke's Medical Center
Denver, Colorado
St. Joseph Hospital
Denver, Colorado
Rose Medical Center
Denver, Colorado
CCOP - Colorado Cancer Research Program
Denver, Colorado
Swedish Medical Center
Englewood, Colorado
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado
North Colorado Medical Center
Greeley, Colorado
Kaiser Permanente - Lafayette
Lafayette, Colorado
Littleton Adventist Hospital
Littleton, Colorado
Sky Ridge Medical Center
Lone Tree, Colorado
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado
McKee Medical Center
Loveland, Colorado
Parker Adventist Hospital
Parker, Colorado
St. Mary - Corwin Regional Medical Center
Pueblo, Colorado
North Suburban Medical Center
Thornton, Colorado
Exempla Lutheran Medical Center
Wheat Ridge, Colorado
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut
Yale Cancer Center
New Haven, Connecticut
Piedmont Hospital
Atlanta, Georgia
Northside Hospital Cancer Center
Atlanta, Georgia
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia
CCOP - Atlanta Regional
Atlanta, Georgia
WellStar Cobb Hospital
Austell, Georgia
John B. Amos Cancer Center
Columbus, Georgia
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia
Piedmont Fayette Hospital
Fayetteville, Georgia
Gwinnett Medical Center
Lawrenceville, Georgia
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia
Southern Regional Medical Center
Riverdale, Georgia
Harbin Clinic Cancer Center - Medical Oncology
Rome, Georgia
Kapiolani Medical Center at Pali Momi
‘Aiea, Hawaii
Oncare Hawaii, Incorporated - Pali Momi
‘Aiea, Hawaii
Showing 40 of 240 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.